# Pediatric Asthma: Diagnosis and Stepwise Management
## Overview
Asthma is the most common chronic disease of childhood, affecting approximately 7 to 8% of U.S. children. Diagnosis in young children relies heavily on clinical assessment, as spirometry is often not feasible before age 5 to 6. Stepwise therapy per the NAEPP EPR-4 guidelines aims to achieve and maintain control with the least amount of medication necessary.
## Diagnosis
### Clinical Features
The hallmark of pediatric asthma is recurrent episodes of wheezing, cough (especially nocturnal or exercise-induced), dyspnea, and chest tightness. These symptoms are typically triggered by viral infections, allergens, exercise, cold air, smoke, and environmental irritants. Improvement with bronchodilator use supports the diagnosis. A family history of atopy, including asthma, allergic rhinitis, and eczema, as well as a personal history of atopic dermatitis, food allergy, or allergic rhinitis, increases the likelihood of asthma.
### Age-Specific Considerations
#### Children Under 5 Years
In children under 5, asthma is a clinical diagnosis because spirometry is not reliable in this age group. The modified Asthma Predictive Index (mAPI) helps predict persistent asthma: it requires recurrent wheezing of 4 or more episodes per year plus either 1 major criterion (parental asthma, atopic dermatitis, or aeroallergen sensitization) or 2 minor criteria (food allergy, wheezing apart from colds, or eosinophilia of 4% or above). A positive mAPI indicates that 77% of these children will have active asthma at school age. Many preschool wheezers will outgrow their symptoms, and viral-induced wheeze is common in this age group. A therapeutic trial of inhaled corticosteroids for 8 to 12 weeks with assessment of response is a reasonable diagnostic and therapeutic approach.
#### Children 6 Years and Older
In children 6 and older, spirometry is the preferred confirmatory test. An obstructive pattern is identified by an FEV1/FVC ratio below the lower limit of normal, typically below 0.85 in children. Bronchodilator reversibility is defined as 12% or greater improvement in FEV1 after short-acting beta-agonist administration. Normal spirometry does not exclude asthma, as values may be normal between episodes. Bronchoprovocation testing with methacholine or exercise challenge is appropriate when spirometry is normal but clinical suspicion is high. Fractional exhaled nitric oxide (FeNO) above 25 ppb supports eosinophilic airway inflammation and predicts response to inhaled corticosteroids; it is a useful adjunct but is not diagnostic in isolation.
### Differential Diagnosis
The differential diagnosis includes viral-induced wheezing (the most common mimic in preschoolers), foreign body aspiration (acute onset with unilateral wheezing), vocal cord dysfunction (inspiratory stridor with normal spirometry and a flattened inspiratory flow-volume loop), tracheomalacia and bronchomalacia, gastroesophageal reflux, cystic fibrosis (failure to thrive with chronic productive cough and recurrent pneumonia), cardiac disease (murmur with failure to thrive), and primary ciliary dyskinesia (chronic wet cough, sinusitis, otitis media, and situs inversus).
## Classification of Asthma Severity (Before Treatment)
Severity is assessed in patients not yet on controller therapy. Intermittent asthma involves symptoms 2 or fewer days per week, nighttime awakenings 2 or fewer times per month, SABA use 2 or fewer days per week, no interference with normal activity, and FEV1 of 80% predicted or above with a normal FEV1/FVC ratio. Mild persistent asthma has symptoms more than 2 days per week but not daily, nighttime awakenings 3 to 4 times per month, SABA use more than 2 days per week but not daily, minor activity limitation, and FEV1 of 80% or above. Moderate persistent asthma involves daily symptoms, nighttime awakenings more than once per week but not nightly, daily SABA use, some activity limitation, and FEV1 between 60 and 80%. Severe persistent asthma features symptoms throughout the day, nightly awakenings (often 7 times per week), SABA use several times daily, extremely limited activity, and FEV1 below 60%.
## Stepwise Therapy (NAEPP EPR-4, 2020 Updates)
### Ages 0-4 Years
Step 1 uses PRN SABA for intermittent asthma. Step 2 adds low-dose ICS daily as the preferred option, with montelukast as an alternative. Step 3 uses medium-dose ICS daily. Step 4 adds medium-dose ICS plus montelukast or referral to a specialist. Step 5 uses high-dose ICS with referral. Step 6 adds high-dose ICS plus oral systemic corticosteroids with referral.
### Ages 5-11 Years
Step 1 uses PRN SABA. Step 2 uses low-dose ICS daily as the preferred option, with montelukast, cromolyn, or theophylline as alternatives. Step 3 prefers low-dose ICS plus LABA, with medium-dose ICS as an alternative. Step 4 uses medium-dose ICS plus LABA. Step 5 uses high-dose ICS plus LABA, with consideration of add-on LAMA (tiotropium) or biologic therapy. Step 6 adds high-dose ICS plus LABA plus oral corticosteroids with referral for biologic therapy.
### Ages 12 Years and Older (and Adults)
Step 1 offers PRN SABA or PRN low-dose ICS-formoterol (preferred per GINA). Step 2 prefers low-dose ICS daily or PRN low-dose ICS-formoterol (GINA-preferred). Step 3 prefers low-dose ICS-LABA daily, with medium-dose ICS as an alternative. Step 4 uses medium-dose ICS-LABA. Step 5 uses high-dose ICS-LABA plus LAMA (tiotropium), with consideration of biologic therapy. Step 6 adds high-dose ICS-LABA plus oral corticosteroids plus biologic therapy.
### Key EPR-4 Updates
PRN ICS-formoterol, known as SMART therapy, is recommended as an alternative reliever for ages 4 and above at appropriate steps and reduces exacerbations compared to SABA-only rescue. LAMA add-on therapy with tiotropium is approved as an add-on for uncontrolled asthma in children 6 and older. Subcutaneous allergen immunotherapy is recommended as an adjunct for persistent allergic asthma in children 5 and older. FeNO-guided therapy can be used to guide ICS dose adjustments in children 5 and older.
## Inhaler Devices by Age
| Age Group | Preferred Device | Alternative |
|-----------|-----------------|-------------|
| <4 years | MDI + spacer + face mask | Nebulizer |
| 4-6 years | MDI + spacer + mouthpiece (no mask) | Nebulizer |
| ≥6 years | MDI + spacer | DPI (if adequate inspiratory flow) |
For children under 4, a metered-dose inhaler with spacer and face mask is preferred, with a nebulizer as an alternative. For ages 4 to 6, an MDI with spacer using a mouthpiece (no mask) is preferred, with nebulizer as an alternative. For children 6 and older, an MDI with spacer is preferred, and a dry powder inhaler is acceptable if adequate inspiratory flow is demonstrated. Proper inhaler technique should be assessed and taught at every visit. Spacer use with an MDI is essential because direct MDI use without a spacer results in approximately 10% lung deposition compared to approximately 20% with a spacer.
## ICS Dosing (Examples)
Low-dose ICS includes fluticasone propionate at 88 mcg per day for ages 0 to 11 or 88 to 264 mcg per day for age 12 and older, or budesonide nebulization at 0.25 to 0.5 mg per day. Medium-dose includes fluticasone propionate at 176 mcg per day for ages 0 to 11 or 264 to 440 mcg per day for age 12 and older. High-dose includes fluticasone propionate at 352 mcg per day for ages 0 to 11 or above 440 mcg per day for age 12 and older. Growth velocity should be monitored annually in children on ICS, though growth suppression is typically small at 0.5 to 1 cm in the first year and is not progressive.
## Asthma Control Assessment
Asthma control should be assessed at every visit using validated tools. The Childhood Asthma Control Test (C-ACT) is used for ages 4 to 11, with a score of 19 or below indicating uncontrolled asthma. The Asthma Control Test (ACT) is used for ages 12 and older, with the same threshold of 19 or below. Domains assessed include symptom frequency, nighttime awakenings, activity limitation, rescue inhaler use, and spirometry when available. When asthma is well controlled, therapy should be stepped down after 3 months of good control. When not well controlled, therapy should be stepped up, but only after verifying adherence, inhaler technique, trigger avoidance, and management of comorbidities.
## Asthma Action Plan
Every patient with asthma should have a written action plan using the color-coded green, yellow, and red zone format. The green zone (doing well) indicates continuing controller medications with no symptoms present. The yellow zone (getting worse) involves increasing SABA use, with potential doubling of ICS or adding oral corticosteroids per the plan. The red zone (medical alert) calls for SABA every 20 minutes for 3 doses, starting oral corticosteroids, and seeking emergency care if no improvement occurs. Copies should be provided to the school nurse and family, and the plan should be reviewed at each visit.
## Acute Exacerbation Management
Mild to moderate exacerbations are managed with SABA via MDI with spacer (4 to 8 puffs) or nebulizer every 20 minutes for 3 doses, along with oral prednisolone or prednisone at 1 to 2 mg/kg/day (maximum 60 mg) for 3 to 5 days. Severe exacerbations require continuous nebulized albuterol, ipratropium bromide, systemic corticosteroids, and consideration of IV magnesium sulfate, with close monitoring. A burst of oral corticosteroids does not require a taper if given for 5 days or fewer. Severity classification should be re-evaluated and controller therapy stepped up following any exacerbation.
## Comorbidity Management
Allergic rhinitis should be treated aggressively with intranasal corticosteroids and antihistamines, as untreated rhinitis worsens asthma control. GERD should be treated if symptomatic, but empiric GERD treatment does not improve asthma outcomes in asymptomatic patients. Obesity management improves asthma control. Allergen triggers should be identified with skin prick or specific IgE testing, with allergen avoidance measures and consideration of allergen immunotherapy. Obstructive sleep apnea should be screened for if symptoms of snoring or poor sleep are present, as it may contribute to poor asthma control.
## Exercise-Induced Bronchoconstriction (EIB)
Exercise-induced bronchoconstriction is common in children with asthma and also occurs in non-asthmatics. Symptoms include cough, wheeze, dyspnea, and chest tightness during or after exercise, peaking 5 to 10 minutes post-exercise. Prevention involves SABA use 15 to 20 minutes before exercise and a warm-up period. If frequent EIB occurs despite SABA pre-treatment, daily ICS or montelukast should be considered. Physical activity should not be restricted; participation with appropriate management should be encouraged.
The NAEPP stepwise therapy approach for pediatric asthma displayed as a staircase diagram for three age groups (0-4, 5-11, 12+) showing medications at each step from Step 1 (SABA only) through Step 6, with preferred and alternative therapies labeled, and arrows indicating step-up and step-down based on asthma control assessment.
An example asthma action plan template in the green-yellow-red zone format showing the green zone (controller medications, no symptoms), yellow zone (increased symptoms with rescue medication instructions and potential ICS dose adjustment), and red zone (emergency actions including SABA frequency, oral corticosteroid dosing, and criteria for calling 911), customized for a pediatric patient.
A visual guide to inhaler devices for children showing the recommended device by age (nebulizer for all ages, MDI with spacer and mask for under 4, MDI with spacer mouthpiece for 4-6, MDI with spacer or DPI for 6+), proper technique illustrations for each device, and common technique errors that reduce drug delivery.
## Clinical Pearls
In children under 5, asthma is a clinical diagnosis, and treatment should not be delayed waiting for spirometry confirmation. A positive modified Asthma Predictive Index in a wheezing preschooler suggests likely persistent asthma and supports initiating controller therapy. Inhaler technique and medication adherence should always be checked before stepping up therapy, as poor technique is the most common cause of apparent treatment failure. PRN ICS-formoterol (SMART therapy) is an evidence-based alternative to SABA-only rescue that reduces exacerbation rates and is endorsed by GINA for ages 4 and above. Growth velocity should be monitored annually in children on ICS, but the small effect of approximately 0.5 cm per year in the first year should not prevent appropriate ICS use. Montelukast carries an FDA boxed warning for neuropsychiatric side effects including mood changes and suicidal ideation; risks should be discussed and the patient monitored, and it should be used as an alternative rather than preferred therapy. Every child with asthma needs a written asthma action plan with copies provided to the school nurse, daycare, and family. A burst of oral corticosteroids lasting 5 days or fewer does not require a taper in children.
## References
- NAEPP Expert Panel Report 4 (EPR-4): Guidelines for the Management of Asthma. NHLBI. 2020
- Global Initiative for Asthma (GINA) Report. 2024
- Castro-Rodriguez JA. The Asthma Predictive Index. Curr Opin Allergy Clin Immunol. 2011
- Szefler SJ et al. Asthma Across the Ages. J Allergy Clin Immunol. 2014
- Kelly HW et al. Effect of Inhaled Glucocorticoids on Growth. N Engl J Med. 2012